Thus, reports on the effects of TGF-β on fibrogenesis during pulmonary fibrosis have suggested that the disruption of TGF-β production or blocking of TGF-β signalling be considered as therapeutic targets of IPF [3]. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.